Patrick Trucchio, an analyst from H.C. Wainwright, maintained the Buy rating on uniQure. The associated price target remains the same with $70.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio has given his Buy rating due to a combination of factors including uniQure’s strong data results and promising pipeline. Despite recent regulatory uncertainties introduced by the FDA regarding the AMT-130 gene therapy for Huntington’s disease, the data remains robust, showing significant slowing of disease progression and sustained biomarker improvements. This underscores the potential of uniQure’s therapies, even as the regulatory path may face delays.
Additionally, uniQure’s financial position is solid, with a substantial cash reserve that extends its operational runway into 2029. The company’s ongoing advancements in other therapeutic areas, such as mesial temporal lobe epilepsy and Fabry disease, further highlight its strategic momentum. These factors collectively support a positive long-term outlook for uniQure, making it a top pick for future growth.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $60.00 price target.